Cross-reactive carbohydrate determinants and allergy diagnosis
Plant and insect allergens often contain glycoproteins with cross-reactive carbohydrate determinants (CCDs). While CCDs are found in many allergens, they do not trigger clinical symptoms. However, patients with IgE antibodies against CCDs frequently receive false-positive results in serum-based allergy tests, leading to confusion in diagnosis.
To improve diagnostic accuracy, Proglycan offers a CCD-blocker that neutralizes the effects of anti-CCD IgE, preventing false positives. Our blocker contains MUXF glycan structures, which have shown high efficacy in thousands of applications. This allows for clearer results and more reliable diagnoses, avoiding the confusion caused by CCDs in allergy tests.
3
Certified Quality: EN ISO 13485:2016
Since October 2022, we have proudly held certification under EN ISO 13485:2016, demonstrating our commitment to the highest standards of quality in the medical device industry. This certification reflects our dedication to delivering safe, reliable, and regulatory-compliant products that meet rigorous international standards.
For our certificates, click below.
Providing innovative allergy diagnostics solutions to improve healthcare outcomes since 2021.
We are dedicated to address the challenge of cross-reactive carbohydrate determinants in allergy diagnostics through our high-quality products, helping to enhance accuracy and reliability in patient care.